Share-based Payment Arrangement, Expense of Hepion Pharmaceuticals, Inc. from 30 Jun 2013 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Hepion Pharmaceuticals, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2013 to 31 Mar 2025.
  • Hepion Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $20,783, a 97% decline year-over-year.
  • Hepion Pharmaceuticals, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $106,658, a 91% decline year-over-year.
  • Hepion Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $791,645, a 67% decline from 2023.
  • Hepion Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $2,416,915, a 5.3% decline from 2022.
  • Hepion Pharmaceuticals, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $2,552,736, a 45% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Hepion Pharmaceuticals, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $106,658 $20,783 -$684,987 -97% 01 Jan 2025 31 Mar 2025 10-Q 19 May 2025 2025 Q1
Q4 2024 $791,645 $28,625 -$121,698 -81% 01 Oct 2024 31 Dec 2024 10-K 08 Apr 2025 2024 FY
Q3 2024 $913,343 $28,625 -$290,286 -91% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $1,203,629 $28,625 +$11,697 +69% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $1,191,932 $705,770 -$1,224,983 -63% 01 Jan 2024 31 Mar 2024 10-Q 19 May 2025 2025 Q1
Q4 2023 $2,416,915 $150,323 -$81,620 -35% 01 Oct 2023 31 Dec 2023 10-K 08 Apr 2025 2024 FY
Q3 2023 $2,498,535 $318,911 -$297,924 -48% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $2,796,459 $16,928 -$145,580 -90% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024 2024 Q2
Q1 2023 $2,942,039 $1,930,753 +$389,303 +25% 01 Jan 2023 31 Mar 2023 10-Q 21 May 2024 2024 Q1
Q4 2022 $2,552,736 $231,943 -$615,577 -73% 01 Oct 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
Q3 2022 $3,168,313 $616,835 -$851,690 -58% 01 Jul 2022 30 Sep 2022 10-Q 20 Nov 2023 2023 Q3
Q2 2022 $4,020,003 $162,508 -$1,232,391 -88% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $5,252,394 $1,541,450 +$583,579 +61% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 $4,668,815 $847,520 01 Oct 2021 31 Dec 2021 10-K 10 Apr 2023 2022 FY
Q3 2021 $1,468,525 +$477,848 +48% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 $1,394,899 +$1,000,288 +253% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022 2022 Q2
Q1 2021 $957,871 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $990,677 01 Jul 2020 30 Sep 2020 10-Q 15 Nov 2021 2021 Q3
Q2 2020 $394,611 01 Apr 2020 30 Jun 2020 10-Q 16 Aug 2021 2021 Q2
Q3 2018 $62,881 -$328,264 -84% 01 Jul 2018 30 Sep 2018 10-Q 14 Nov 2018 2018 Q3
Q2 2018 $152,764 -$120,465 -44% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2018 2018 Q2
Q1 2018 $217,387 -$337,085 -61% 01 Jan 2018 31 Mar 2018 10-Q 15 May 2018 2018 Q1
Q3 2017 $391,145 -$109,971 -22% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $273,229 01 Apr 2017 30 Jun 2017 10-Q 14 Aug 2018 2018 Q2
Q1 2017 $554,472 01 Jan 2017 31 Mar 2017 10-Q 15 May 2018 2018 Q1
Q3 2016 $501,116 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2018 Q1
Q2 2015 $2,118,187 $929,199 +$878,048 +1717% 01 Apr 2015 30 Jun 2015 10-K 25 Sep 2015 2015 FY
Q1 2015 $1,240,139 $677,916 +$534,693 +373% 01 Jan 2015 31 Mar 2015 10-Q 14 May 2015 2015 Q3
Q4 2014 $705,446 $399,060 +$398,208 +46738% 01 Oct 2014 31 Dec 2014 10-Q 12 Feb 2015 2015 Q2
Q3 2014 $307,238 $112,012 +$112,012 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2014 2015 Q1
Q2 2014 $195,226 $51,151 +$51,151 01 Apr 2014 30 Jun 2014 10-K 25 Sep 2015 2015 FY
Q1 2014 $144,075 $143,223 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q3
Q4 2013 $852 01 Oct 2013 31 Dec 2013 10-Q 12 Feb 2015 2015 Q2
Q3 2013 $0 01 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014 2015 Q1
Q2 2013 $0 15 May 2013 30 Jun 2013 10-K 29 Sep 2014 2014 FY

Hepion Pharmaceuticals, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $791,645 -$1,625,270 -67% 01 Jan 2024 31 Dec 2024 10-K 08 Apr 2025 2024 FY
2023 $2,416,915 -$135,821 -5.3% 01 Jan 2023 31 Dec 2023 10-K 08 Apr 2025 2024 FY
2022 $2,552,736 -$2,116,079 -45% 01 Jan 2022 31 Dec 2022 10-K 16 Apr 2024 2023 FY
2021 $4,668,815 +$2,289,455 +96% 01 Jan 2021 31 Dec 2021 10-K 10 Apr 2023 2022 FY
2020 $2,379,360 01 Jan 2020 31 Dec 2020 10-K 08 Apr 2022 2021 FY
2015 $2,118,187 +$1,922,961 +985% 01 Jul 2014 30 Jun 2015 10-K 25 Sep 2015 2015 FY
2014 $195,226 01 Jul 2013 30 Jun 2014 10-K 25 Sep 2015 2015 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.